These final results, together with a previous report demonstrating that a small-molecule ACKR3 agonist CCX771 exhibits anxiolytic-like actions in mice,2 assistance the notion of targeting ACKR3 as a singular technique to modulate the opioid procedure, which could open new therapeutic avenues for opioid-associated disorders.At that time, Microsoft A